Potential Effects of Traditional Chinese Medicine on COVID-19 and Cardiac Injury: Mechanisms and Clinical Evidence

References

• World Health Organization. Press conferences on COVID-19 and other global health issues. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019. Accessed May 22, 2023.
   Google Scholar
• Parohan M, Yaghoubi S, Seraji A. Cardiac injury is associated with severe outcome and death in patients with Coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of observational studies. Eur Heart J Acute Cardiovasc Care. 2020;9(6):665–677. doi:10.1177/2048872620937165
   PubMed Web of Science ®Google Scholar
• Lala A, Johnson KW, Januzzi JL, et al. Prevalence and impact of myocardial injury in patients hospitalized with COVID-19 infection. J Am Coll Cardiol. 2020;76(5):533–546. doi:10.1016/j.jacc.2020.06.007
   PubMed Web of Science ®Google Scholar
• Yu Y, Xu D, Fu S, et al. Patients with COVID-19 in 19 ICUs in Wuhan, China: a cross-sectional study. Crit Care. 2020;24(1):219. doi:10.1186/s13054-020-02939-x
   PubMed Web of Science ®Google Scholar
• Lindholt JS, Søgaard R, Rasmussen LM, et al. Five-year outcomes of the Danish cardiovascular screening (DANCAVAS) trial. N Engl J Med. 2022;387(15):1385–1394. doi:10.1056/NEJMoa2208681
   PubMed Web of Science ®Google Scholar
• Kite TA, Ludman PF, Gale CP, et al. International prospective registry of acute coronary syndromes in patients with COVID-19. J Am Coll Cardiol. 2021;77(20):2466–2476. doi:10.1016/j.jacc.2021.03.309
   PubMed Web of Science ®Google Scholar
• Ng TM, Toews ML. Impaired norepinephrine regulation of monocyte inflammatory cytokine balance in heart failure. World J Cardiol. 2016;8(10):584–589. doi:10.4330/wjc.v8.i10.584
   PubMedGoogle Scholar
• Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062. doi:10.1016/s0140-6736(20)30566-3
   PubMed Web of Science ®Google Scholar
• Arentz M, Yim E, Klaff L, et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. JAMA. 2020;323(16):1612–1614. doi:10.1001/jama.2020.4326
   PubMed Web of Science ®Google Scholar
• Hu C, Liang M, Gong F, He B, Zhao D, Zhang G. Efficacy of lianhua qingwen compared with conventional drugs in the treatment of common pneumonia and COVID-19 pneumonia: a meta-analysis. Evid Based Complement Alternat Med. 2020;2020:5157089. doi:10.1155/2020/5157089
   PubMed Web of Science ®Google Scholar
• Zeng SY, Liu YF, Liu JH, Zeng ZL, Xie H, Liu JH. Potential effects of akkermansia muciniphila in aging and aging-related diseases: current evidence and perspectives. Aging Dis. 2023;2023:1. doi:10.14336/ad.2023.0325
   Google Scholar
• Liu Z, Guo F, Wang Y, et al. BATMAN-TCM: a bioinformatics analysis tool for molecular mechanism of traditional Chinese medicine. Sci Rep. 2016;6:21146. doi:10.1038/srep21146
   PubMed Web of Science ®Google Scholar
• Tai W, He L, Zhang X, et al. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol Immunol. 2020;17(6):613–620. doi:10.1038/s41423-020-0400-4
   PubMed Web of Science ®Google Scholar
• Turner AJ, Hiscox JA, Hooper NM. ACE2: from vasopeptidase to SARS virus receptor. Trends Pharmacol Sci. 2004;25(6):291–294. doi:10.1016/j.tips.2004.04.001
   PubMed Web of Science ®Google Scholar
• Zhang XZ, Gao Y, Liu Y, et al. Screening of potential inhibitors against SARS-CoV-2 based on prescription mining and molecular dynamics simulations. Prog Biochem Biophys. 2022:1–13. doi:10.16476/j.pibb.2022.0224
   Web of Science ®Google Scholar
• Chen X, Wu Y, Chen C, et al. Identifying potential anti-COVID-19 pharmacological components of traditional Chinese medicine Lianhuaqingwen capsule based on human exposure and ACE2 biochromatography screening. Acta Pharm Sin B. 2021;11(1):222–236. doi:10.1016/j.apsb.2020.10.002
   PubMed Web of Science ®Google Scholar
• Ho TY, Wu SL, Chen JC, Li CC, Hsiang CY. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction. Antiviral Res. 2007;74(2):92–101. doi:10.1016/j.antiviral.2006.04.014
   PubMed Web of Science ®Google Scholar
• Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr HW. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet. 2003;361(9374):2045–2046. doi:10.1016/s0140-6736(03)13615-x
   PubMed Web of Science ®Google Scholar
• Pu-yang G, Yu-jie G, Xiao-peng L, Nan W, Jian G. Exploring active compounds of Jinhua Qinggan Granules for prevention of COVID-19 based on network pharmacology and molecular docking. Chinese Traditional and Herbal Drugs. 2020;51(07):1685–1693.
   Google Scholar
• Gomaa AA, Abdel-Wadood YA. The potential of glycyrrhizin and licorice extract in combating COVID-19 and associated conditions. Phytomed Plus. 2021;1(3):100043. doi:10.1016/j.phyplu.2021.100043
   PubMedGoogle Scholar
• Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420–422. doi:10.1016/s2213-2600(20)30076-x
   PubMed Web of Science ®Google Scholar
• Xu B, Sun X. Inflammation in the myocardial injury and repair. J Clin Cardiol. 2018;34(7):633–635. doi:10.13201/j.issn.1001-1439.2018.07.001
   Google Scholar
• Imanaka-Yoshida K. Inflammation in myocardial disease: from myocarditis to dilated cardiomyopathy. Pathol Int. 2020;70(1):1–11. doi:10.1111/pin.12868
   PubMed Web of Science ®Google Scholar
• Xu HF, Meng L, Yao J, et al. Myocardial expression of Spry1 and MAPK proteins of viral myocarditis. Fa Yi Xue Za Zhi. 2013;29(3):164–167.
   PubMedGoogle Scholar
• Guzik TJ, Mohiddin SA, Dimarco A, et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res. 2020;116(10):1666–1687. doi:10.1093/cvr/cvaa106
   PubMed Web of Science ®Google Scholar
• Musher DM, Abers MS, Corrales-Medina VF. Acute infection and myocardial infarction. N Engl J Med. 2019;380(2):171–176. doi:10.1056/NEJMra1808137
   PubMed Web of Science ®Google Scholar
• Birra D, Benucci M, Landolfi L, et al. COVID 19: a clue from innate immunity. Immunol Res. 2020;68(3):161–168. doi:10.1007/s12026-020-09137-5
   PubMed Web of Science ®Google Scholar
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi:10.1016/s0140-6736(20)30183-5
   PubMed Web of Science ®Google Scholar
• Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513. doi:10.1016/s0140-6736(20)30211-7
   PubMed Web of Science ®Google Scholar
• Tajbakhsh A, Gheibi Hayat SM, Taghizadeh H, et al. COVID-19 and cardiac injury: clinical manifestations, biomarkers, mechanisms, diagnosis, treatment, and follow up. Expert Rev Anti Infect Ther. 2021;19(3):345–357. doi:10.1080/14787210.2020.1822737
   PubMed Web of Science ®Google Scholar
• Liu J, Li S, Liu J, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine. 2020;55:102763. doi:10.1016/j.ebiom.2020.102763
   PubMed Web of Science ®Google Scholar
• Niu WH, Wu F, Cao WY, Wu ZG, Chao YC, Liang C. Network pharmacology for the identification of phytochemicals in traditional Chinese medicine for COVID-19 that may regulate interleukin-6. Biosci Rep. 2021;41(1). doi:10.1042/BSR20202583
   Web of Science ®Google Scholar
• Ruan X, Du P, Zhao K, et al. Mechanism of Dayuanyin in the treatment of coronavirus disease 2019 based on network pharmacology and molecular docking. Chin Med. 2020;15:62. doi:10.1186/s13020-020-00346-6
   PubMed Web of Science ®Google Scholar
• Runfeng L, Yunlong H, Jicheng H, et al. Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2). Pharmacol Res. 2020;156:104761. doi:10.1016/j.phrs.2020.104761
   PubMed Web of Science ®Google Scholar
• Xia L, Shi Y, Su J, et al. Shufeng Jiedu, a promising herbal therapy for moderate COVID-19: Antiviral and anti-inflammatory properties, pathways of bioactive compounds, and a clinical real-world pragmatic study. Phytomedicine. 2021;85:153390. doi:10.1016/j.phymed.2020.153390
   PubMed Web of Science ®Google Scholar
• Wang ZZ, Li K, Maskey AR, et al. A small molecule compound berberine as an orally active therapeutic candidate against COVID-19 and SARS: a computational and mechanistic study. FASEB j. 2021;35(4):e21360. doi:10.1096/fj.202001792R
   PubMed Web of Science ®Google Scholar
• Bai Z, Li P, Wen J, et al. Inhibitory effects and mechanisms of the anti-covid-19 traditional Chinese prescription, Keguan-1, on acute lung injury. J Ethnopharmacol. 2022;285:114838. doi:10.1016/j.jep.2021.114838
   PubMed Web of Science ®Google Scholar
• Wei WL, Wu SF, Li HJ, et al. Chemical profiling of Huashi Baidu prescription, an effective anti-COVID-19 TCM formula, by UPLC-Q-TOF/MS. Chin J Nat Med. 2021;19(6):473–480. doi:10.1016/s1875-5364(21)60046-8
   PubMed Web of Science ®Google Scholar
• Lin JW, Cherng YG, Chen LJ, Niu HS, Chang CK, Niu CS. Ginseng is useful to enhance cardiac contractility in animals. Biomed Res Int. 2014;2014:723084. doi:10.1155/2014/723084
   PubMed Web of Science ®Google Scholar
• Wu ZL, Ren H, Lai WY, et al. Scleroderma of Poria cocos exerts its diuretic effect via suppression of renal aquaporin-2 expression in rats with chronic heart failure. J Ethnopharmacol. 2014;155(1):563–571. doi:10.1016/j.jep.2014.05.054
   PubMed Web of Science ®Google Scholar
• Ma J, Ma S, Yin C, Wu H. Shengmai San-derived herbal prevents the development of a vulnerable substrate for atrial fibrillation in a rat model of ischemic heart failure. Bio Pharmaco. 2018;100:156–167. doi:10.1016/j.biopha.2018.02.013
   Google Scholar
• Li C, Wang Y, Qiu Q, et al. Qishenyiqi protects ligation-induced left ventricular remodeling by attenuating inflammation and fibrosis via STAT3 and NF-κB signaling pathway. PLoS One. 2014;9(8):e104255. doi:10.1371/journal.pone.0104255
   PubMed Web of Science ®Google Scholar
• Xiao J, Deng SB, She Q, et al. Traditional Chinese medicine Qili qiangxin inhibits cardiomyocyte apoptosis in rats following myocardial infarction. Exp Ther Med. 2015;10(5):1817–1823. doi:10.3892/etm.2015.2759
   PubMed Web of Science ®Google Scholar
• Meng Y, Du Z, Li Y, et al. Integration of metabolomics with pharmacodynamics to elucidate the anti-myocardial ischemia effects of combination of notoginseng total saponins and safflower total flavonoids. Front Pharmacol. 2018;9:667. doi:10.3389/fphar.2018.00667
   PubMed Web of Science ®Google Scholar
• Wang H, Jiang W, Hu Y, et al. Quercetin improves atrial fibrillation through inhibiting TGF-β/Smads pathway via promoting MiR-135b expression. Phytomedicine. 2021;93:153774. doi:10.1016/j.phymed.2021.153774
   PubMed Web of Science ®Google Scholar
• Zhou X, Liu J, Li J. Effects and mechanism of quercetin on blood pressure intestinal flora and ventricular remodeling in spontaneously hypertensive rats. Nat Prod Resd Dev. 2020;32(9):1449–1455. doi:10.16333/j.1001-6880.2020.9.001
   Google Scholar
• Liu G, Yang W, Wang Y, Zhang F. The effect of puerarin on the arrhythmia induced by ischemia/reperfusion injury in rats myocardium. Ann Appl Biol. 2020;39(07):3350–3354. doi:10.13417/j.gab.039.003350
   Google Scholar
• Guo S, Xue YJ, Zhu X, Yang B, Zhou CZ. Effects and pharmacological mechanism of Zhigancao Decoction on electrical and structural remodeling of the atrium of rabbits induced by rapid atrial pacing. J Interv Card Electrophysiol. 2023;66(3):597–609. doi:10.1007/s10840-022-01356-0
   PubMed Web of Science ®Google Scholar
• Li X, Tian G, Xu L, et al. Wenxin keli for the treatment of arrhythmia-systems pharmacology and in vivo pharmacological assessment. Front Pharmacol. 2021;12:704622. doi:10.3389/fphar.2021.704622
   PubMed Web of Science ®Google Scholar
• Xu H, Lu R, Liu N, Wen F. Antiarrhythmic effect and mechanism of Anlv capsule. Chin J Gerontol. 2019;39(12):2836–2838.
   Google Scholar
• Yang Y, Su C, Zhang XZ, et al. Mechanisms of Xuefu Zhuyu Decoction in the treatment of coronary heart disease based on integrated metabolomics and network pharmacology approach. J Chromatogr B Analyt Technol Biomed Life Sci. 2023;1223:123712. doi:10.1016/j.jchromb.2023.123712
   PubMed Web of Science ®Google Scholar
• Gao J, Pan Y, Zhao Y, et al. Network pharmacology study on molecular mechanisms of Zhishi Xiebai Guizhi decoction in the treatment of coronary heart disease. Evid Based Complement Alternat Med. 2021;2021:3574321. doi:10.1155/2021/3574321
   PubMedGoogle Scholar
• Zhang J, Xue S, Chen H, et al. Exploring the mechanism of si-miao-yong-an decoction in the treatment of coronary heart disease based on network pharmacology and experimental verification. Comb Chem High Throughput Screen. 2023;26. doi:10.2174/1386207326666230703150803
   Google Scholar
• Cui Y, Zhang F, Xu W, et al. Effects of Si-Miao-Yong-An decoction on myocardial I/R rats by regulating gut microbiota to inhibit LPS-induced TLR4/NF-κB signaling pathway. BMC Complement Med Ther. 2023;23(1):180. doi:10.1186/s12906-023-04013-9
   PubMedGoogle Scholar
• Fan Y, Liu J, Miao J, et al. Anti-inflammatory activity of the Tongmai Yangxin pill in the treatment of coronary heart disease is associated with estrogen receptor and NF-κB signaling pathway. J Ethnopharmacol. 2021;276:114106. doi:10.1016/j.jep.2021.114106
   PubMed Web of Science ®Google Scholar
• Rey JR, Caro-Codón J, Rosillo SO, et al. Heart failure in COVID-19 patients: prevalence, incidence and prognostic implications. Eur J Heart Fail. 2020;22(12):2205–2215. doi:10.1002/ejhf.1990
   PubMed Web of Science ®Google Scholar
• Yudong P, Kai M, Hongquan G, et al. Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV. Chin J Cardiol. 2020;48:450–455. doi:10.3760/cma.j.cn112148-20200220-00105
   Google Scholar
• Li X, Zhang J, Huang J, et al. A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effects of qili qiangxin capsules in patients with chronic heart failure. J Am Coll Cardiol. 2013;62(12):1065–1072. doi:10.1016/j.jacc.2013.05.035
   PubMed Web of Science ®Google Scholar
• Lu X, Zhang L, Wang J, et al. Clinical efficacy and safety of xinmailong injection for the treatment of chronic heart failure: a meta-analysis. Front Pharmacol. 2018;9:810. doi:10.3389/fphar.2018.00810
   PubMed Web of Science ®Google Scholar
• Heart Failure Group of Chinese Society of Cardiology of Chinese Medical Association, Heart Failure Professional Committee of Chinese Medical Doctor Association, Editorial Board of the Chinese Journal of Cardiovascular Diseases. Chinese heart failure diagnosis and treatment guidelines 2018. Chin J Cardiol. 2018;46(10):760–789. doi:10.3760/cma.j.issn.0253-3758.2018.10.004
   Google Scholar
• Li L, Zhang J, Xu F. Clinical study on lixin pill in treating congestive heart failure. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2000;20(5):341–343.
   PubMedGoogle Scholar
• Fu XX, Lu J, Yang F, Xiao WJ. Treatment of chronic heart failure of Xin-Shen yang deficiency, interior retention of water-fluid syndrome by external application of Zhuangshenling recipe combined with western medicine: a clinical study. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2014;34(7):808–811.
   PubMedGoogle Scholar
• Jiang B, Chen J, Xu L, et al. Salvianolic acid B functioned as a competitive inhibitor of matrix metalloproteinase-9 and efficiently prevented cardiac remodeling. BMC Pharmacol. 2010;10:10. doi:10.1186/1471-2210-10-10
   PubMedGoogle Scholar
• Long B, Brady WJ, Koyfman A, Gottlieb M. Cardiovascular complications in COVID-19. Am J Emerg Med. 2020;38(7):1504–1507. doi:10.1016/j.ajem.2020.04.048
   PubMed Web of Science ®Google Scholar
• He H, Han G, Li X, et al. Efficacy and safety of Chinese medicine in treating arrhythmia: meta-analysis of randomized controlled trials. Evid Based Complement Alternat Med. 2021;2021:9960471. doi:10.1155/2021/9960471
   PubMedGoogle Scholar
• Alexander LK, Keene BW, Small JD, Yount B, Baric RS. Electrocardiographic changes following rabbit coronavirus-induced myocarditis and dilated cardiomyopathy. Adv Exp Med Biol. 1993;342:365–370. doi:10.1007/978-1-4615-2996-5_56
   PubMedGoogle Scholar
• Wu CI, Postema PG, Arbelo E, et al. SARS-CoV-2, COVID-19, and inherited arrhythmia syndromes. Heart Rhythm. 2020;17(9):1456–1462. doi:10.1016/j.hrthm.2020.03.024
   PubMed Web of Science ®Google Scholar
• Kochi AN, Tagliari AP, Forleo GB, Fassini GM, Tondo C. Cardiac and arrhythmic complications in patients with COVID-19. J Cardiovasc Electrophysiol. 2020;31(5):1003–1008. doi:10.1111/jce.14479
   PubMed Web of Science ®Google Scholar
• Hua W, Gao RL, Zhao BC, et al. The efficacy and safety of wenxin keli in patients with frequent premature ventricular contractions: a randomized, double-blind, placebo-controlled, parallel-group, multicenter trial. Chin Med J. 2015;128(19):2557–2564. doi:10.4103/0366-6999.166026
   PubMed Web of Science ®Google Scholar
• Wang X, Wang T, Ding S, Ma YL. Xin su ning-a review of basic and clinical pharmacology integrated with traditional Chinese medicine antiarrhythmic theory. Front Pharmacol. 2021;12:657484. doi:10.3389/fphar.2021.657484
   PubMed Web of Science ®Google Scholar
• Yang HJ, Kong B, Shuai W, Zhang JJ, Huang H. Shensong yangxin protects against metabolic syndrome-induced ventricular arrhythmias by inhibiting electrical remodeling. Front Pharmacol. 2020;11:993. doi:10.3389/fphar.2020.00993
   PubMed Web of Science ®Google Scholar
• Wang X, Hu D, Dang S, et al. Effects of traditional Chinese medicine shensong yangxin capsules on heart rhythm and function in congestive heart failure patients with frequent ventricular premature complexes: a randomized, double-blind, multicenter clinical trial. Chin Med J. 2017;130(14):1639–1647. doi:10.4103/0366-6999.209906
   PubMed Web of Science ®Google Scholar
• Babapoor-Farrokhran S, Gill D, Walker J, Rasekhi RT, Bozorgnia B, Amanullah A. Myocardial injury and COVID-19: possible mechanisms. Life Sci. 2020;253:117723. doi:10.1016/j.lfs.2020.117723
   PubMed Web of Science ®Google Scholar
• Giustino G, Croft LB, Stefanini GG, et al. Characterization of myocardial injury in patients with COVID-19. J Am Coll Cardiol. 2020;76(18):2043–2055. doi:10.1016/j.jacc.2020.08.069
   PubMed Web of Science ®Google Scholar
• Jaiswal V, Sarfraz Z, Sarfraz A, et al. COVID-19 infection and myocarditis: a state-of-The-Art systematic review. J Prim Care Community Health. 2021;12:21501327211056800. doi:10.1177/21501327211056800
   Web of Science ®Google Scholar
• Li B, Yang J, Zhao F, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020;109(5):531–538. doi:10.1007/s00392-020-01626-9
   PubMed Web of Science ®Google Scholar
• Gao S, Li L, Li L, et al. Effects of the combination of tanshinone IIA and puerarin on cardiac function and inflammatory response in myocardial ischemia mice. J Mol Cell Cardiol. 2019;137:59–70. doi:10.1016/j.yjmcc.2019.09.012
   PubMed Web of Science ®Google Scholar
• Xie F, Wu YY, Duan GJ, et al. Anti-myocardial ischemia reperfusion injury mechanism of dried ginger-aconite decoction based on network pharmacology. Front Pharmacol. 2021;12:609702. doi:10.3389/fphar.2021.609702
   PubMed Web of Science ®Google Scholar
• Wang J, He QY, Zhang YL. Effect of shenshao tablet on the quality of life for coronary heart disease patients with stable angina pectoris. Chin J Integr Med. 2009;15(5):328–332. doi:10.1007/s11655-009-0328-0
   PubMed Web of Science ®Google Scholar
• Shaha KB, Manandhar DN, Cho JR, Adhikari A, KC MB. COVID-19 and the heart: what we have learnt so far. Postgrad Med J. 2021;97(1152):655–666. doi:10.1136/postgradmedj-2020-138284
   PubMed Web of Science ®Google Scholar
• Wu HL, Wang X, Li XM, Luo WJ, Deng TT. Trial study on DENG Tie-tao’s coronary heart disease capsules in improving patients’ quality of life. Chin J Integr Med. 2005;11(3):173–178. doi:10.1007/bf02836499
   PubMedGoogle Scholar
• Wei H, Wu H, Yu W, Yan X, Zhang X. Shenfu decoction as adjuvant therapy for improving quality of life and hepatic dysfunction in patients with symptomatic chronic heart failure. J Ethnopharmacol. 2015;169:347–355. doi:10.1016/j.jep.2015.04.016
   PubMed Web of Science ®Google Scholar
• Chen GH, Xu CS, Zhang J, et al. Inhibition of miR-128-3p by tongxinluo protects human cardiomyocytes from ischemia/reperfusion injury via upregulation of p70s6k1/p-p70s6k1. Front Pharmacol. 2017;8:775. doi:10.3389/fphar.2017.00775
   PubMed Web of Science ®Google Scholar
• Li Q, Li N, Cui HH, et al. Tongxinluo exerts protective effects via anti-apoptotic and pro-autophagic mechanisms by activating AMPK pathway in infarcted rat hearts. Exp Physiol. 2017;102(4):422–435. doi:10.1113/ep086192
   PubMed Web of Science ®Google Scholar
• Wang B, Yang Q, Bai WW, et al. Tongxinluo protects against pressure overload-induced heart failure in mice involving VEGF/Akt/eNOS pathway activation. PLoS One. 2014;9(6):e98047. doi:10.1371/journal.pone.0098047
   PubMed Web of Science ®Google Scholar
• Li XD, Yang YJ, Geng YJ, et al. Tongxinluo reduces myocardial no-reflow and ischemia-reperfusion injury by stimulating the phosphorylation of eNOS via the PKA pathway. Am J Physiol Heart Circ Physiol. 2010;299(4):H1255–61. doi:10.1152/ajpheart.00459.2010
   PubMed Web of Science ®Google Scholar
• Wang S-H, Wang J, Li J. 丹蒌片治疗痰瘀互阻型冠心病心绞痛的疗效评价[Efficacy assessment of treating patients with coronary heart disease angina of phlegm and stasis mutual obstruction syndrome by Danlou tablet]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2012;32(8):1051–1055. Chinese.
   PubMedGoogle Scholar
• Ge JB, Fan WH, Zhou JM, et al. Efficacy and safety of Shexiang Baoxin pill (MUSKARDIA) in patients with stable coronary artery disease: a multicenter, double-blind, placebo-controlled Phase IV randomized clinical trial. Chin Med J. 2020;134(2):185–192. doi:10.1097/cm9.0000000000001257
   Web of Science ®Google Scholar